Aduro Biotech Inc (KDNY)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

1600 FAIRVIEW AVE E. SEATTLE, WA 98102

Aduro Biotech, Inc provides immunotherapy services. The Company develops technology and vaccines for the treatment of early stage cancer and mesothelin-expressing tumors. Aduro Biotech serves customers in the United States.

Data as of 2021-05-08 11:39:43 -0400
Market Cap689.144 Million Shares Outstanding42.383 Million Avg 30-day Volume388.836 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-5.88 Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.21786 52-week High/Low21.68 / 10.5 Next Earnings Date Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from KDNY instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 0 1 (0.06%) 0 (0.0%)
Funds Holding: 76 71 7.04% 24 (1.44%) 21 (1.31%) 14.29%
13F shares: 23.63 Million 7.533 Million 213.68% 12.69 Million 3.794 Million 234.46%
% Ownership 56.0508 17.8686 213.68% 30.1019 9.0002 234.46%
New Positions: 24 8 200.0% 8 2 300.0%
Increased Positions 29 13 123.08% 10 3 233.33%
Closed Positions 18 27 -33.33% 5 12 -58.33%
Reduced Positions 16 29 -44.83% 6 11 -45.45%
Total Calls 27.041 Thousand 2.426 Thousand 1014.63% 13.4 Thousand 2.38 Thousand 463.03%
Total Puts 66.326 Thousand 2.007 Thousand 3204.73% 46.7 Thousand 2 Thousand 2235.0%
PUT/CALL Ratio 2.45 0.83 195.18% 3.49 0.84 315.48%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding KDNY (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KDNY BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

FROHLICH TOM CHIEF BUSINESS OFFICER

  • Officer
0 2021-02-10 3

DOBMEIER ERIC PRESIDENT, CEO

  • Officer
  • Director
0 2021-02-10 7

KING ANDREW JAMES HEAD OF RENAL DISCOVERY

  • Officer
0 2021-02-10 3

GLICKLICH ALAN CHIEF MEDICAL OFFICER

  • Officer
0 2021-02-10 3

BJERKHOLT ERIC CHIEF FINANCIAL OFFICER

  • Officer
0 2021-02-10 3

GREENMAN WILLIAM MARINER

  • Director
0 2020-10-06 1

HAGHIGHAT ROSS

  • Director
0 2020-10-06 2

GRIFFIN MICHELLE RENEE

  • Director
0 2020-10-06 2

THOMAS DOLCA

  • Director
0 2020-10-06 2

JEREL DAVIS

  • Director
0 2020-10-05 2

VERSANT VENTURE CAPITAL VII, L.P.

VERSANT VOYAGEURS I PARALLEL, L.P.

VERSANT VOYAGEURS I, L.P.

  • 10% Owner
7,888,369 2020-10-05 1

AKKARAJU SRINIVAS

  • Director
0 2020-10-05 2

ISAACS STEPHEN T PRESIDENT AND CEO

  • Officer
  • Director
288,098 2020-09-15 1

TEMPLEMAN BLAINE CHIEF LEGAL OFFICER

  • Officer
121,916 2020-09-15 3

FERBER CELESTE SVP, GC AND SECRETARY

  • Officer
38,687 2020-09-15 3

NUYTEN DIMITRY SA CHIEF MEDICAL OFFICER

  • Officer
8,462 2020-08-07 2

KACHIOFF WILLIAM G INTERIM CFO

  • Officer
10,000 2020-06-01 1

OBRIEN STEPHANIE MONAGHAN

  • Director
0 2020-05-05 0

SHERWIN STEPHEN A

  • Director
0 2020-05-05 0

MACK DAVID HENRY

  • Director
0 2020-05-05 0

KARBE FRANK

  • Director
0 2020-05-05 0

VAN ELSAS ANDREA CHIEF SCIENTIFIC OFFICER

  • Officer
438,367 2020-02-25 0

WELCH JAMES H SEE REMARKS

  • Officer
0 2019-07-15 0

LEW JENNIFER CHIEF FINANCIAL OFFICER

  • Officer
135,155 2019-05-01 0

HOTH DANIEL FLOYD JR INTERIM CHIEF MEDICAL OFFICER

  • Officer
0 2018-11-29 0

SACKS NATALIE CHIEF MEDICAL OFFICER

  • Officer
173,720 2018-09-12 0

CHAN GERALD

  • Director
0 2018-06-06 0

MCCORMICK FRANK

  • Director
0 2018-06-06 0

SCHAFER GREGORY W CHIEF OPERATING OFFICER

  • Officer
254,062 2018-01-25 0

MORNINGSIDE VENTURE (VI) INVESTMENTS LTD

  • 10% Owner
9,305,532 2017-12-31 0

BROCKSTEDT DIRK G. EVP OF RESEARCH AND DEV.

  • Officer
124,603 2017-12-29 0

DUBENSKY THOMAS W. CHIEF SCIENTIFIC OFFICER

  • Officer
39,900 2017-08-10 0

ULTIMATE KEEN LTD

  • 10% Owner
5,602,499 2015-04-20 0

ROGERS JOHN E. AND LOIS A.

  • 10% Owner
148,245 2015-04-20 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 22:15:04 UTC -0.3257 0.3757 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 21:45:02 UTC -0.3257 0.3757 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 21:15:02 UTC -0.3257 0.3757 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 20:45:03 UTC -0.3421 0.3921 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 20:15:03 UTC -0.3421 0.3921 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 19:45:03 UTC -0.3421 0.3921 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 19:15:03 UTC -0.3421 0.3921 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 18:45:03 UTC -0.3421 0.3921 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 18:15:03 UTC -0.3421 0.3921 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 17:45:02 UTC -0.3685 0.4185 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 17:15:03 UTC -0.3685 0.4185 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 16:45:03 UTC -0.3685 0.4185 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 16:15:03 UTC -0.3685 0.4185 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 15:45:03 UTC -0.3685 0.4185 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 15:15:03 UTC -0.3685 0.4185 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 14:45:04 UTC -0.2932 0.3432 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 14:15:04 UTC -0.2932 0.3432 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 13:45:04 UTC -0.2932 0.3432 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 13:15:03 UTC -0.2932 0.3432 25000
CHINOOK THERAPEUTICS INC KDNY 2021-05-10 12:45:02 UTC -0.2932 0.3432 25000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments